N@N

Health Rounds: Vaccine keeps advanced kidney cancer from recurring

The article from Reuters discusses a new study presented at the American Society of Clinical Oncology's Genitourinary Cancers Symposium, which found that a personalized mRNA vaccine, when combined with Merck's immunotherapy Keytruda, significantly reduced the risk of recurrence or death in patients with advanced kidney cancer. The study involved 104 patients who had their tumors surgically removed; half received the vaccine plus Keytruda, while the other half received Keytruda alone. After about two years, 78.6% of those treated with the combination therapy were alive and cancer-free, compared to 58.8% in the Keytruda-only group. This represents a 47% reduction in the risk of recurrence or death. The vaccine, developed by Moderna, uses the same technology as its COVID-19 vaccine, tailoring it to the genetic makeup of each patient's tumor to enhance the immune response against cancer cells.

Read the Full Reuters Article at:
[ https://www.reuters.com/business/healthcare-pharmaceuticals/health-rounds-vaccine-keeps-advanced-kidney-cancer-recurring-2025-02-07/ ]